Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 55 Records) |
| Query Trace: Epilepsy and CYP2C9[original query] |
|---|
| CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. The pharmacogenomics journal 2015 Jun . Ortega-Vázquez A, Dorado P, Fricke-Galindo I, Jung-Cook H, Monroy-Jaramillo N, Martínez-Juárez I E, Familiar-López I, Peñas-Lledó E, LLerena A, López-López |
| Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy. Personalized medicine 2015 Jun 12 (3): 199-207. Tóth Katalin, B?di Tamás, Kiss Ádám, Temesvári Manna, Háfra Edit, Nagy Andrea, Szever Zsuzsa, Monostory Katal |
| Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance. International journal of clinical pharmacology and therapeutics 2015 Jul 53 (7): 504-16. Kousar Shazia, Wafai Zahoor A, Wani Mushtaq A, Jan Tariq R, Andrabi Khurshid |
| Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. Journal of human genetics 2015 Aug 60 (8): 413-7. Suvichapanich Supharat, Jittikoon Jiraphun, Wichukchinda Nuanjun, Kamchaisatian Wasu, Visudtibhan Anannit, Benjapopitak Suwat, Nakornchai Somjai, Manuyakorn Wiparat, Mahasirimongkol Surakame |
| Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region. Drugs in R&D 2017 Jul . Dagenais Renée, Wilby Kyle John, Elewa Hazem, Ensom Mary H |
| Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity. Basic & clinical pharmacology & toxicology 2017 Mar . Zhao Mingming, Zhang Ti, Li Guofei, Qiu Feng, Sun Yaxin, Zhao Lim |
| Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacological reports : PR 2017 Jan 69 (3): 504-511. López-García Miguel A, Feria-Romero Iris A, Serrano Héctor, Rayo-Mares Darío, Fagiolino Pietro, Vázquez Marta, Escamilla-Núñez Consuelo, Grijalva Israel, Escalante-Santiago David, Orozco-Suarez Sand |
| A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy. Journal of Ayurveda and integrative medicine 2017 Mar . Thaker Saket J, Gandhe Prajakta P, Godbole Charuta J, Bendkhale Shital R, Mali Nitin B, Thatte Urmila M, Gogtay Nithya |
| A Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic Information. PloS one 2017 12 (1): e0169214. Silva-Alves Mariana S, Secolin Rodrigo, Carvalho Benilton S, Yasuda Clarissa L, Bilevicius Elizabeth, Alvim Marina K M, Santos Renato O, Maurer-Morelli Claudia V, Cendes Fernando, Lopes-Cendes Isc |
| Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. Basic & clinical pharmacology & toxicology 2018 May . Zhu Xu, Li Xinlin, Zhang Ti, Zhao Lim |
| CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Pharmacogenomics and personalized medicine 2018 4 11 51-58. Silvado Carlos Eduardo, Terra Vera Cristina, Twardowschy Carlos Alexand |
| Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy. European journal of hospital pharmacy : science and practice 2020 Aug . Song Cangsang, Li Xingde, Mao Panpan, Song Wenbing, Liu Lu, Zhang Ya |
| CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study. Acta neurologica Belgica 2020 Jul . Eltalal Samah, El Ayouty Mostafa, El-Said Afaf, Wahba Yah |
| An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children. The International journal of neuroscience 2020 6 131 (12): 1147-1154. Makowska Marianna, Smolarz Beata, Bry? Magdalena, Forma Ewa, Romanowicz Han |
| Possible Genetic Determinants of Response to Phenytoin in a Group of Colombian Patients With Epilepsy. Frontiers in pharmacology 2020 11 555. Calderon-Ospina Carlos Alberto, Galvez Jubby Marcela, López-Cabra Claudia, Morales Natalia, Restrepo Carlos Martín, Rodríguez Jesús, Aristizábal-Gutiérrez Fabio Ancízar, Velez-van-Meerbeke Alberto, Laissue Paul, Fonseca-Mendoza Dora Jane |
| Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. European journal of clinical pharmacology 2020 May . Yoon Ha Young, Ahn Min Hyoung, Yee Jeong, Lee Nari, Han Ji Min, Gwak Hye S |
| Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy. Pharmacogenomics and personalized medicine 2021 9 14 1133-1140. El-Tallawy Hamdy N, Abuhamdah Sawsan, Nassar Ahmed Y, Farghaly Wafaa M A, Saleem Tahia H, Atta Sara A, Sayed Ayat A, Tohamy Amal M, Hassan Mohammed |
| The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis. Annals of translational medicine 2021 6 9 (10): 846. Fang Huihui, Wang Xiaojuan, Hou Kelu, Zhang Ying, Shao Shuai, Zhang Guijie, Feng Yufei, Huang L |
| Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy. Frontiers in pediatrics 2021 2 8 599044. Xu Ze-Yue, Guo Hong-Li, Li Ling, Zhang Min, Jing Xia, Xu Ze-Jun, Qiu Jin-Chun, Lu Xiao-Peng, Ding Xuan-Sheng, Chen Feng, Xu Ji |
| Genetic Analysis of CYP2C9 with Reference to Drug Response in Epilepsy Patients of Pakistan. Genetics research 2022 2022 1451007. Maqbool Hafsa, Saleem Tayyaba, Sheikh Nadeem, Ashfaq Aq |
| VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4. Wiadomosci lekarskie (Warsaw, Poland : 1960) 2023 6 76 (5 pt 1): 1007-1013. Liudmyla M Tantsura, Olena Yu Pylypets, Dmytro V Tretiakov, Yevhen O Tantsu |
| Study of genetic variants and their clinical significance in Mexican pediatric patients with epilepsy. Gene 2023 6 877 147565. Iris A Feria-Romero, Aracely Reyes-Cuayahuitl, Justina Sosa-Maldonado, Alexia V Montes-Aparicio, Darío Rayo-Mares, Daniel Pérez-Pérez, Israel Grijalva-Otero, Sandra Orozco-Suar |
| A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. Epilepsia open 2023 2 . Riva Antonella, Roberti Roberta, D'Onofrio Gianluca, Stella Vari Maria, Amadori Elisabetta, De Giorgis Valentina, Cerminara Caterina, Specchio Nicola, Pietrafusa Nicola, Tombini Mario, Assenza Giovanni, Cappanera Silvia, Marini Carla, Rasmini Paolo, Veggiotti Pierangelo, Zara Federico, Russo Emilio, Striano Pasqua |
| Polymorphisms Affecting the Response to Novel Antiepileptic Drugs. International journal of molecular sciences 2023 2 24 (3): . Urzì Brancati Valentina, Pinto Vraca Tiziana, Minutoli Letteria, Pallio Giovan |
| Impact of CYP2C9*2 and *3 polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case-control study. Personalized medicine 2023 10 . Kirubakaran Ramakrishnan, Ramasamy Kesavan, Shravan Venkatraman, Sunil K Narayan, Ramachandran Ramesh Kumar, Deepak Shewa |
| Association of variants in the ABCB1, CYP2C19 and CYP2C9 genes for Juvenile Myoclonic Epilepsy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023 10 . Aurelio Jara-Prado, Jorge Luis Guerrero-Camacho, Quetzalli Denisse Ángeles-López, Adriana Ochoa-Morales, David José Dávila-Ortiz de Montellano, Miguel Ángel Ramírez-García, Michelle Breda-Yepes, Reyna M Durón, Antonio V Delgado-Escueta, Diego A Barrios-González, Iris E Martínez-Juár |
| Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients. Pharmacogenomics 2023 1 24 (3): 153-162. Zheng Xiao-Xiao, You Yu-Xin, Zhao Lin-Lin, Du Yan, Xu Sheng-Qiu, Tang Dao-Qu |
| Overview of preclinical and clinical studies investigating pharmacokinetics and drug-drug interactions of padsevonil. Expert opinion on drug metabolism & toxicology 2024 6 . Hugues Chanteux, Merran MacPherson, Hester Kramer, Christian Otoul, Takuya Okagaki, Chiara Rospo, Steven De Bruyn, Mark Watling, Massimo Bani, David Sciberr |
| Effects of CYP2C19 and CYP2C9 polymorphisms on the efficacy and plasma concentration of lacosamide in pediatric patients with epilepsy in China. European journal of pediatrics 2024 12 184 (1): 73. Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, Jing Yu, Jie Feng, Long Cui, Ke-Fang Sun, Yan Sun, Lu-Hai |
| Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients with Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy. Therapeutic drug monitoring 2024 1 . Bingsuo Ma, Kun Yang, Xinping Li, Ning Su, Ting Yu, Yan Zou, Xingmeng Xu, Fei Wang, Jingdong Cheng, Zijun Yan, Tong Chen, Liangming Zha |
- Page last reviewed:Feb 1, 2024
- Content source: